Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis-Reference-Cited by-同舟云学术

Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis

Published:2022-01 Issue:1 Volume:20 Page:136-144.e31
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Shah Eric D.^ORCID,Salwen-Deremer Jessica K.,Gibson Peter R.,Muir Jane G.,Eswaran Shanti,Chey William D.

Funder

Meso Scale Diagnostics

Takeda Pharmaceutical Company

Pfizer

AGA Research Foundation

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference61 articles.

1. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review;Sperber;Gut,2017

2. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis;Lovell;Clin Gastroenterol Hepatol,2012

3. Economic burden of irritable bowel syndrome with diarrhea: retrospective analysis of a U.S. commercially insured population;Buono;J Manag Care Spec Pharm,2017

4. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018;Peery;Gastroenterology,2019

5. American College of Gastroenterology monograph on management of irritable bowel syndrome;Ford;Am J Gastroenterol,2018

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synbiotics as Treatment for Irritable Bowel Syndrome: A Review;Microorganisms;2024-07-21

2. Algorithms or biomarkers in patients with lower DGBI?;Neurogastroenterology & Motility;2024-06-27

3. Effectiveness of a Balanced Nine-Strain Synbiotic in Primary-Care Irritable Bowel Syndrome Patients—A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial;Nutrients;2024-05-16

4. The function of the gut microbiota–bile acid–TGR5 axis in diarrhea-predominant irritable bowel syndrome;mSystems;2024-03-19

5. Differences in provider recommendations for Black/African American and White patients with irritable bowel syndrome;Neurogastroenterology & Motility;2024-01-23